ADAPTIVE AND INNATE IMMUNE RESPONSES
TRIGGERED TO NEUTRALIZE GASTRIN HORMONES
AS A THERAPY FOR GI CANCERS

NEWS FLASH

April 2018: TYG oncology has successfully manufactured reference material. This was 50% funded by Cancer Research UK. This milestone marks the end of our collaboration with CR-UK and we thank them for their non-dilutive, pre-clinical funding and clinical trial planning. We appreciate their independent and unbiased support for our novel approach for treating pancreatic cancer using active checkpoint control immunotherapy coupled with a proven antigen that neutralizes gastrin hormones. 

Dr Geert Mudde will be presenting at the 3rd Annual Advances in Immuno-Oncology Congress (organized by Oxford Global) on 24th of May at the Inmarsat Building, 99 City Road Conference Centre, London

Dr Geert Mudde will be presenting at the 6th European Biopharma Congress 18-19 September, Hyatt Place Amsterdam Airport Amsterdam.


March 2016: OncoQR and TYG oncology Ltd announce the expansion of their collaboration agreement to tackle additional cancers. http://tinyurl.com/zcyzelp

March 2016: OncoQR announces the preclinical dose-ranging findings for TYG100. A single dose achieved clinical levels of antibodies in NHP including patients treated concurrently with gemcitabine. 
http://tinyurl.com/jptsq4z

February 2016:  Experimental Cancer Medicines Centres in Leeds, Glasgow and Belfast design parallel first-in-human trials in pancreatic and gastroesophageal cancers for TYG100.

November 2014: TYG oncology files for patent protection of TYG100.

April 2014: on behalf of TYG, Dr. Paul Broome presented the TYG100 technology at the annual AACR meeting. Historically clinically relevant titres of gastrin neutralising antibodies obtained in earlier Phase 3 trials were exceeded >100 fold with TYG100 with no serious adverse events.

March 2014:  DANIEL D. VON HOFF, M.D., F.A.C.P., a world renowned expert in the field of pancreatic advises the company on critical Phase 2 trial design.

March 2014:  GRAHAM DOCKRAY, Emeritus Professor of Physiology at the University of Liverpool, is welcomed as a new member of it's scientific advisory board January 2013: TYG oncology Ltd registered - Companies House, UK. 

[Sleeker_special_clear]